PubMed ID:
29111115
Public Release Type:
Journal
Publication Year: 2018
Affiliation: Temple University, Philadelphia, PA.
DOI:
https://doi.org/10.1053/j.gastro.2017.08.033
Authors:
Serrano J,
Abell TL,
Abell TL,
Alvarado B,
Baxter L,
Belt P,
Bernard C,
Brown A,
Clarke JO,
Clarke JO,
Connery S,
Culler S,
DeVole N,
Dhalla S,
Dhalla S,
Dodge J,
Donithan M,
Earle K,
Farrugia G,
Farrugia G,
Garay G,
Gomez Y,
Grover M,
Grover M,
Hallinan E,
Hall S,
Hamilton F,
Hamilton FA,
Hasler WL,
Hasler WL,
Hatter L,
Herman W,
Howard R,
Isaacson M,
James S,
Kim Y,
Kirkeby K,
Koch KL,
Koch KL,
Kraftson A,
Lee C,
Lee LA,
Lee LA,
Lin M,
Mauer A,
May PK,
McCallum RW,
McCallum RW,
Miriel L,
Miriel LA,
Nguyen LAB,
Nguyen LAB,
NIDDK Gastroparesis Clinical Research Consortium (GpCRC),
Nowotny L,
Orlando C,
Orthey P,
Palit A,
Parkman HP,
Parkman HP,
Pasricha PJ,
Pasricha PJ,
Ponting K,
Romero R,
Rothberg AE,
Sarosiek I,
Sarosiek I,
Snape WJ,
Snape WJ,
Stein E,
Stein EM,
Sternberg A,
Stuart P,
Tonascia J,
Tonascia J,
Torrance R,
Van Natta M,
Van Natta ML,
Vega N,
Wagoner A,
Wilson L,
Wootten S,
Yates KP,
Yates KP,
Yee G
Studies:
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome.